Regenxbio (RGNX) Operating Leases (2019 - 2025)

Regenxbio's Operating Leases history runs 7 years deep, the most recent figure standing at $65.2 million for Q4 2025.

• On a quarterly basis, Operating Leases fell 12.03% year-over-year to $65.2 million in Q4 2025; TTM through Dec 2025 was $65.2 million, a 12.03% decrease from a year earlier, with the FY2025 full-year figure at $65.2 million, down 12.03% from the prior year.
• Operating Leases fell to $65.2 million in Q4 2025 per RGNX's latest filing, from $67.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $88.8 million in Q4 2022 and bottomed at $65.2 million in Q4 2025.
• The 5-year median for Operating Leases is $82.3 million (2021), against an average of $79.6 million.
• Across the five-year window, Operating Leases soared 1062.78% in 2021 and declined 12.03% in 2025, its largest moves.
• Year by year, Operating Leases stood at $84.9 million in 2021, then grew by 4.56% to $88.8 million in 2022, then fell by 7.41% to $82.2 million in 2023, then slipped by 9.84% to $74.1 million in 2024, then decreased by 12.03% to $65.2 million in 2025.
• Per Business Quant, the three latest RGNX Operating Leases figures stand at $65.2 million (Q4 2025), $67.4 million (Q3 2025), and $69.6 million (Q2 2025).